Association of plasma growth arrest-specific protein 6 (Gas6) concentrations with albuminuria in patients with type 2 diabetes

Erek-Toprak, Aybala; Bingöl-Ozakpinar, Özlem; Karaca, Zeynep; Çıkrıkçıoğlu, Mehmet Ali; Hurşitoğlu, Mehmet; Uras, Ahmet Rıza; Adeli, Khosrow; Uras, Fi̇kri̇ye

doi:10.3109/0886022x.2014.883997

Cited by 15 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,6 Besides the animal experiments and cell culture studies, our previous study has shown that in type 2 diabetic patients with micro-and macroalbuminuria, GAS6 concentration was higher than the control group, and positive correlation exists between albuminuria and plasma GAS6 levels. 1 In a recent study comparing GAS6 intron 8 c.834 + 7G4A polymorphism in subjects with type 2 diabetes, impaired glucose tolerance and controls, it was shown that AA genotype is protective against type 2 diabetes, and for individuals with AA genotype, plasma GAS6 protein levels are higher compared to individuals with GG genotype. 8 This genotype was also found to be protective from type 2 diabetes as well as acute coronary syndrome and stroke.…”

Section: Discussionmentioning

confidence: 99%

“…1 Diabetic nephropathy develops in about 20 to 40% of type 2 diabetes patients, and it is not known why it is not seen in all of the patients with diabetes mellitus type 2.…”

Section: Introductionmentioning

confidence: 99%

“…5,6 A positive correlation was shown between albuminuria and serum levels of GAS6 in type 2 diabetic individuals. 1 Chromosomal localization of GAS6 gene is 13q34. 7 A single nucleotide polymorphism (c.834 + 7G4A) of this gene in intron 8 was demonstrated to be protective against stroke, diabetes and acute coronary syndrome.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

GAS6intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy

et al. 2015

Self Cite

View full text Add to dashboard Cite

Background -Aim: In animal experiments, growth arrest-specific 6 (Gas6) protein plays a key role in the development of mesangial cell and glomerular hypertrophy in the early phase of diabetic nephropathy, and diabetic nephropathy is prevented by warfarin-induced inhibition of GAS6 protein. It was shown that GAS6 intron 8 c.834 + 7G4A polymorphism is protective against type 2 diabetes mellitus, and AA genotype is associated with higher blood levels of GAS6 protein. Our aim is to investigate whether this polymorphism is a risk factor for diabetic nephropathy in type 2 diabetes mellitus. Method: Eighty-seven patients with diabetic nephropathy were compared with 66 non-diabetic controls in terms of GAS6 intron 8 c.834 + 7G4A polymorphism. Patients with history of stroke, ischemic heart disease were excluded. Each patient was examined by the ophthalmologist to determine diabetic retinopathy. Results: Frequency of GG, GA and AA genotypes are similar in diabetic nephropathy and control groups according to GAS6 intron 8 c.834 + 7G4A polymorphism (p ¼ 0.837). Rate of diabetic retinopathy was 54.02%. In the subgroup analysis, GA genotype was significantly more frequent than GG genotype in patients with diabetic retinopathy when compared to without diabetic retinopathy (p ¼ 0.010). Conclusion: In our study, GAS6 intron 8 c.834 + 7G4A polymorphism was not associated with diabetic nephropathy in type 2 diabetes mellitus. However, heterozygous state of this polymorphism may be a risk factor for diabetic retinopathy in patients with diabetic nephropathy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…1 Diabetic nephropathy develops in about 20 to 40% of type 2 diabetes patients, and it is not known why it is not seen in all of the patients with diabetes mellitus type 2.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

GAS6intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Erek-Toprak et al [8] showed that plasma Gas6 levels were higher in diabetic patients with micro or macroalbuminuria compared to diabetic patients with normoalbuminuria and healthy controls. Hyde et al [9] have shown that the up-regulation of Gas6/Axl signalling has a protective mechanism which reduces tubulointerstitial apoptosis and slows progression to end stage renal failure in the partial nephrectomy and high phosphate diet model of mice.…”

Section: Introductionmentioning

confidence: 99%

Glomerülonefritli hastalarda karotis intima media kalınlığının prediktörü hangisidir; nötrofil-lenfosit oranı mı proteinüri mi?

Toraman¹,

Eren²,

Düzgün³

et al. 2019

Pamukkale Medical Journal

View full text Add to dashboard Cite

show abstract

“…The human GAS6 sandwich ELISA development kit (R&D Systems, Inc., Minneapolis, MN, USA) and a Substrate Reagent Pack (Color reagent A&B) (R&D Systems, Inc.) were used to measure plasma GAS6 levels. ELISA was performed in line with our previous publications [17,18]. The human GAS6 sandwich ELISA development kit (R&D) was designed for the analysis of cell culture supernatants and was not optimized by the manufacturers for analysis of human plasma when we started first time.…”

Section: Elisa Of Plasma Gas6mentioning

confidence: 99%

Growth Arrest‐Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis

Sünbül

Cagman

Gerin³

et al. 2015

Cardiovascular Therapeutics

Self Cite

View full text Add to dashboard Cite

SUMMARYObjectives: An increased risk for cardiovascular disease with psoriasis has been reported. Growth Arrest-Specific 6 (GAS6) amplifies pro-inflammatory endothelial cell activation via TAM receptors. However, it also inhibits inflammation by multiple mechanisms including phagocytosis. The objective of this study was to investigate whether plasma GAS6 levels are associated with conventional cardiometabolic (CM) risk factors in patients with psoriasis. Methods: Forty patients diagnosed with psoriasis (22 male, mean age: 43.3 AE 13.8 years) and 40 age-/sex-matched healthy controls (22 male, mean age: 39.3 AE 8.9 years) were included in the study. CM risk factors (hypertension, hyperlipidemia, diabetes mellitus, and cigarette smoking) were identified. GAS6 levels were measured by ELISA. Results: There were no significant differences between the plasma GAS6 levels of patients with psoriasis compared to the control group (6.6 AE 2.0 ng/mL, 7.6 AE 2.8 ng/mL, respectively, P > 0.05). However, GAS6 levels of patients with psoriasis having a smoking history (n = 11) were significantly lower than both patients with psoriasis who had no smoking history (n = 29) and controls (5.5 AE 1.7 ng/mL, 6.9 AE 1.9 ng/mL, 7.6 AE 2.8 ng/mL, respectively, P < 0.05). Similarly, psoriasis patients with at least one CM risk factor showed lower GAS6 levels compared to subjects without any CM risk factor (5.7 AE 1.7 ng/mL, 7.3 AE 2.0 ng/mL, P < 0.01). There was no correlation between the GAS6 level, disease duration or PASI score (r = 0.150, À0.150, and P = 0.310, 0.398, respectively). Conclusions: This pilot study provides the first evidence in humans for an association between low plasma GAS6 levels and conventional risk factors in psoriasis. Further large scale, prospective studies are needed to confirm these results.

show abstract

Association of plasma growth arrest-specific protein 6 (Gas6) concentrations with albuminuria in patients with type 2 diabetes

Cited by 15 publications

References 36 publications

GAS6intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy

GAS6intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy

Glomerülonefritli hastalarda karotis intima media kalınlığının prediktörü hangisidir; nötrofil-lenfosit oranı mı proteinüri mi?

Growth Arrest‐Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis

Contact Info

Product

Resources

About